Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 3, 2007, Pages 353-359

  Torp, Sverre Helge ^a   Gulati, S ^a   Johannessen, E ^a   Dalen, A ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Astrocytomas; Brain tumours; EGFR; Gliomas; Immunohistochemistry; Oncogenes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADULT; AGED; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 35348883191     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Kleihues P., Burger P.C., Collins V.P., Newcomb E.W., Ohgaki H., Cavenee W.K.: Glioblastoma. In: Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000:29-39.
2. Weiner H. L.: The role of growth factor receptors in central nervous system development and neoplasia. Neurosurgery 37:179-194, 1995.
3. Hamel W., Westphal M.: Growth factors in gliomas revisited. Acta Neurochir. 142:113-138, 2000.
4. Kuan C-T., Wikstrand C.J., Bigner D.D.: EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 8:83-96, 2001.
5. Bazley L.A., Gullick W.J.: The epidermal growth factor receptor family. Endocr. Relat, Cancer 12:S17-27, 2005.
6. Schlessinger J.: Cell signaling by receptor tyrosine kinases. Cell 103:211-225, 2000.
7. Libermann T.A., Nusbaum H.R., Razon N., et al.: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313:144-147, 1985.
8. Bigner S.H., Burger P.C., Wong A.J., et al.: Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J. Neuropathol. Exp. Neurol. 47:191-205, 1988.
9. Helseth E., Unsgaard G., Dalen A., et al.: Amplification of the epidermal growth factor receptor gene in biopsy specimens from human intracranial tumours. Br. J. Neurosurg. 2:217-225, 1988.
10. Ekstrand A.J., James C.D., Cavenee W.K. et al.: Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51:2164-2172, 1991.
11. Torp S.H., Helseth E., Dalen A., et al.: Epidermal growth factor receptor expression in human gliomas. Cancer Immunol. Immunother. 33:61-64, 1991
12. Torp S.H., Helseth E., Ryan L., et al.: Amplification of the epi-dermal growth factor receptor gene in human gliomas. Anticancer Res. 11:2095-2098, 1991.
13. Hiesiger E.M., Hayes R.L., Pierz D.M., et al.: Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J. Neurooncol. 16:93-104, 1993.
14. Schlegel J., Stumm G., Brändle K., et al.: Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J. Neurooncol. 22:201-207, 1994.
15. Schober R., Bilzer T., Waha A., et al.: The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin. Neuropathol. 14:169-174, 1995.
16. Reifenberger J., Ring G.U., Gies U., et al.: Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J. Neuropathol. Exp. Neurol. 55:822-831, 1996.
17. Waha A., Baumann A., Wolf H.K., et al.: Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-α pathway in human astrocytic gliomas. J. Neurosurg. 85:634-641, 1996.
18. Wikstrand C.J., McLendon R.E., Friedman A.H., et al.: Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 57:4130-4140, 1997.
19. Bouvier-Labit C., Chinot O., Ochi C., et al.: Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropath. Appl. Neurobiol. 24:381-388, 1998.
20. Newcomb E.W., Cohen H., Lee S.R., et al.: Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. 8:655-667, 1998.
21. Feldkamp M.M., Lala P., Lau N., et al.: Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45:1442-1453, 1999.
22. Simmons M.L., Lamborn K,R., Takahashi M., et al.: Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 61:1122-1128, 2001.
23. Shinojima N., Tada K., Shiraishi S., et al.: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63:6962-6970, 2003.
24. Aldape K.D., Ballman K., Furth A., et al.: Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J. Neuropathol. Exp. Neurol. 63:700-707, 2004.
25. Andersson U., Guo D., Maimer B., et al.: Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol. 108:135-142, 2004.
26. Biernat W., Huang H., Yokoo H., et al.: Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol. 14:131-136, 2004.
27. Marquez A., Wu R., Zhao J., et al.: Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn. Mol. Pathol. 13:1-8, 2004.
28. Torp S.H., Bringedal K., Dalen A.: Immunohistochemical detection of epidermal growth factor receptor in human high-grade astrocytomas - a comparison between frozen- and paraffin sections. J. Exp. Clin. Cancer Res. 24:89-92, 2005.
29. Layfield L.J., Willmore C., Tripp S., et al.: Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl. Immunohistochem. Molecul. Morphol. 14:91-96, 2006.
30. Torp S.H., Helseth E., Unsgaard G., et al.: C-erbB-2/HER-2 protein in human intracranial tumours. Eur. J. Cancer 29A: 1604-1606, 1993
31. Schwechheimer K., Läufle R.M., Schmahl W., et al.: Expression of neu/c-erbB-2 in human brain tumors. Hum. Pathol. 25:772-780,1994.
32. Westphal M., Meima L., Szonyi E., et al.: Heregulins and the ErbB-2/3/4 receptors in gliomas. J. Neurooncol. 35:335-346, 1997.
33. Haapasalo H., Hyytinen E., Sallinen P., et al.: C-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridisation. Br. J. Cancer 73:620-623, 1996.
34. Srinivasan R., Poulsom R., Hurst H.C., et al.: Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J. Pathol. 185:236-245, 1998
35. Potti A., Forseen S.E., Koka V.K., et al.: Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest. 22:537-544, 2004.
36. Herbst R.S., Shin D.M.: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. A new paradigm for cancer therapy. Cancer 94:1593-1611, 2002.
37. Mischel P.S., Cloughesy T.F.: Targeted molecular therapy of GBM. Brain Pathol. 13:52-61, 2003.
38. Halatsch M.-E., Schmidt U., Behnke-Mursch J., et al.: Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat. Rev. 32;74-89, 2006.
39. Aas T., Børressen A.-L., Geisler S., et al.: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med. 2:811-814, 1996.
40. Stefansson I.M., Salvesen H.B., Akslen L.A.: Prognostic impact of alterations in P-Cadherin expression and related cell adhesion markers in endometrial cancer. J. Clin. Oncol. 22:1242-1252, 2004.
41. Chan P.T.H., Weller R.O.: Factors influencing tumour cell and vascular proliferation in glioblastomas (Abstract). Neuropath. Appl. Neurobiol. 28:155-156, 2002.
42. Singleton T.P., Niehans G.A., Gu F., et al.: Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum. Pathol. 23:1141-1150, 1992.
43. Busmanis I., Feleppa F., Jones A., et al.: Analysis of c-erbB2 expression using a panel of 6 commercially available antibodies. Pathology 26:261-267, 1994.
44. Press M.F., Hung G., Godolphin W., et al.: Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 54:2771-2777, 1994.
45. Slamon D.J., Godolphin W., Jones L.A., et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989.